<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03818308</url>
  </required_header>
  <id_info>
    <org_study_id>HepNet-aHCV-V</org_study_id>
    <secondary_id>2018-003474-27</secondary_id>
    <nct_id>NCT03818308</nct_id>
  </id_info>
  <brief_title>Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir</brief_title>
  <official_title>Multicenter Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Fix Dose combination_The HepNet Acute HCV-V Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HepNet Study House, German Liverfoundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Center for Infection Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm multicenter pilot study to evaluate the efficacy and safety of treatment
      with sofosbuvir (SOF)/velpatasvir (VEL) fix dose combination (FDC) in patients with acute
      hepatitis C virus (HCV) infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm multicenter pilot study to evaluate the efficacy and safety of treatment
      with SOF/VEL FDC for 8 weeks in patients with acute HCV infection as measured by the
      proportion of subjects with sustained viral response (undetectable HCV RNA) 12 weeks after
      stop of therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, open-label, single-arm multicenter, phase II pilot trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with sustained virological response (undetectable HCV RNA) 12 weeks after discontinuation of therapy</measure>
    <time_frame>12 weeks after discontinuation of therapy</time_frame>
    <description>Measured by the portion of subjects with sustained virological response (undetectable HCV RNA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean HCV RNA viral load at baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks after stop of therapy</measure>
    <time_frame>at baseline, after 2 weeks, 4 weeks and 8 weeks of therapy, and 12 weeks after stop of therapy</time_frame>
    <description>Measured by mean HCV RNA viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who reached ALT normalization (ALT &lt; ULN) after 8 weeks of therapy and 12 weeks after discontinuation of therapy</measure>
    <time_frame>after 8 weeks of therapy, and 12 weeks after discontinuation of therapy</time_frame>
    <description>Measured by the proportion of subjects who reached ALT normalization (ALT &lt; ULN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of frequency and severity of adverse events (AEs)</measure>
    <time_frame>through study completion, an average of 20 weeks</time_frame>
    <description>Collection of all AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Acute Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir and Velpatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOF/VEL FDC film-coated tablet, oral, SOF 400 mg/VEL 100 mg daily, 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir and Velpatasvir</intervention_name>
    <description>All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.</description>
    <arm_group_label>Sofosbuvir and Velpatasvir</arm_group_label>
    <other_name>Epclusa 400 mg/100 mg film-coated tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to provide written informed consent

          2. Male or female, age &gt; 18 years

          3. HCV RNA &gt; 10^3 IU/mL at screening

          4. Confirmation of acute HCV infection documented by either:

               1. Documented seroconversion to HCV antibody (anti-HCV) positivity within the 4
                  months preceding screening

               2. Documented conversion to HCV RNA positivity within the 4 months preceding
                  screening

               3. or known or suspected exposure to HCV within the 4 months preceding screening
                  with 10 times elevated serum ALT level at screening or 4 month preceding
                  screening without evidence of confounding liver disorders

          5. Body mass index (BMI) ≥18 kg/m2

          6. Subjects must have the following laboratory parameters at screening:

               1. INR ≤ 1.5 x ULN unless subject has known hemophilia or is stable on an
                  anticoagulant regimen affecting INR

               2. HbA1c ≤ 10%

               3. Creatinine clearance (CLcr) ≥ 30 mL/min, as calculated by the Cockcroft-Gault
                  equation (using actual body weight)

          7. A negative serum pregnancy test is required for female subjects (unless surgically
             sterile or women ≥ 54 years of age with cessation for 24 ≥ months of previously
             occurring menses). Complete abstinence from intercourse. Periodic abstinence (e.g.,
             calendar, ovulation, symptothermal, post-ovulation methods) is not permitted.

             Or

             Consistent and correct use of 1 of the following methods of birth control listed
             below, in addition to a male partner who correctly uses a condom, from the date of
             Screening until the end of follow up:

               -  intrauterine device (IUD) with a failure rate of &lt; 1% per year

               -  female barrier method: cervical cap or diaphragm with spermicidal agent

               -  tubal sterilization

               -  vasectomy in male partner

               -  hormone-containing contraceptive:

                    -  implants of levonorgestrel

                    -  injectable progesterone

                    -  oral contraceptives (either combined or progesterone only)

                    -  contraceptive vaginal ring

                    -  transdermal contraceptive patch

          8. Subject must be able to comply with the dosing instructions for study drug
             administration and be able to complete the study schedule of assessments

        Exclusion Criteria:

          1. Subject has been treated with any investigational drug or device within 42 days of the
             Screening visit

          2. Co-Infection with HIV

          3. Clinically-significant illness (other than HCV) or any other major medical disorder
             that, in the opinion of the investigator, may interfere with subject treatment,
             assessment or compliance with the protocol.

          4. Solid organ transplantation

          5. Gastrointestinal disorder or post-operative condition that could interfere with the
             absorption of the study drug (for example, gastric bypass or severe ulcerative
             colitis).

          6. Clinical signs of hepatic decompensation (i.e., clinical ascites, encephalopathy or
             variceal hemorrhage).

          7. Difficulty with blood collection and/or poor venous access for the purposes of
             phlebotomy.

          8. Psychiatric hospitalization, suicide attempt, and/or a period of disability as a
             result of their psychiatric illness within the last 2 years. Subjects with psychiatric
             illness that is well-controlled on a stable treatment regimen for at least 12 months
             prior to screening or has not required medication in the last 12 months may be
             included.

          9. Significant drug allergy (such as anaphylaxis or hepatotoxicity).

         10. Pregnant or nursing female

         11. Clinically-relevant drug or alcohol abuse that significantly impairs patient
             compliance. Uncontrolled users of intravenous drugs will not be permitted to enroll in
             the study.

         12. Clinical relevant (not controlled) liver disease of a non-HCV etiology (e.g.,
             hemochromatosis, autoimmune hepatitis, alcoholic liver disease, Wilson's disease, α1
             antitrypsin deficiency, cholangitis)

         13. Use of any prohibited concomitant medications within 21 days before the Baseline/Day 1
             visit. The use of amiodarone is prohibited from 60 days prior to Day 1 through the end
             of treatment;

         14. Known hypersensitivity to SOF/VEL or formulation excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Cornberg, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School, Clinic for Gastroenterology, Hepatology, and Endocrinology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Cornberg, Prof. Dr.</last_name>
    <phone>+49511532</phone>
    <phone_ext>6821</phone_ext>
    <email>cornberg.markus@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia Kahlhöfer, Dr.</last_name>
    <phone>+49 511 532</phone>
    <phone_ext>6817</phone_ext>
    <email>kahlhoefer.julia@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Allgemeinmedizinische und internistische Praxis</name>
      <address>
        <city>Berlin-Friedrichshain</city>
        <zip>10243</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Cordes, Dr.</last_name>
      <phone>+493097002288</phone>
      <email>studien@praxiswarschauer33.de</email>
    </contact>
    <investigator>
      <last_name>Christiane Cordes, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentrum für Infektiologie Prenzlauer Berg</name>
      <address>
        <city>Berlin</city>
        <zip>10349</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Ingiliz, Dr.</last_name>
      <phone>0049 30 451988</phone>
      <phone_ext>9415</phone_ext>
      <email>studienzentrum@zibp.de</email>
    </contact>
    <investigator>
      <last_name>Patrick Ingiliz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum, Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Müller, PD Dr.</last_name>
      <phone>0049 30 45056</phone>
      <phone_ext>5207</phone_ext>
      <email>tobias.mueller@charite.de</email>
    </contact>
    <investigator>
      <last_name>Tobias Müller, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Hüneburg, Dr.</last_name>
      <phone>0049 228 2871</phone>
      <phone_ext>5260</phone_ext>
      <email>hepa.studienambulanz@ukbonn.de</email>
    </contact>
    <investigator>
      <last_name>Robert Hüneburg, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Gastroenterologie und Hepatologie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gudrun Hilgard, Dr.</last_name>
      <phone>0049 201 723</phone>
      <phone_ext>3610</phone_ext>
      <email>gudrun.hilgard@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Gudrun Hilgard, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe-Universität Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Zeuzem, Prof. Dr.</last_name>
      <phone>0049 69 6301</phone>
      <phone_ext>6204</phone_ext>
      <email>zeuzem@em.uni-frankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Zeuzem, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infektionsmedizinisches Centrum Hamburg (ICH) Study Center</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Jürgen Stellbrink, Prof. Dr.</last_name>
      <phone>0049 40 2840</phone>
      <phone_ext>7370</phone_ext>
      <email>mail@ich-studycenter.com</email>
    </contact>
    <investigator>
      <last_name>Hans-Jürgen Stellbrink, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, I. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Schulze zur Wiesch, PD Dr.</last_name>
      <phone>0049 40 74105</phone>
      <phone_ext>7981</phone_ext>
      <email>v.schlicker@uke.de</email>
    </contact>
    <investigator>
      <last_name>Julian Schulze zur Wiesch, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Innere Medizin, Klinik für Gastroenterologie, Hepatologie und Endokrinologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Cornberg, Prof. Dr.</last_name>
      <phone>0049 511 532</phone>
      <phone_ext>6821</phone_ext>
      <email>cornberg.markus@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Marcus Cornberg, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Hohenstaufenring</name>
      <address>
        <city>Köln</city>
        <zip>50674</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Scholten, Dr.</last_name>
      <phone>0049 221 35505</phone>
      <phone_ext>450</phone_ext>
      <email>studien@phsr.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Scholten, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Klinik und Poliklinik für Gastroenterologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Wiegand, Prof. Dr.</last_name>
      <phone>0049 341 971</phone>
      <phone_ext>2330</phone_ext>
      <email>johannes.wiegand@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Wiegand, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU-München, II Medizinische Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Spinner, PD Dr.</last_name>
      <phone>0049 89 4140</phone>
      <phone_ext>5236</phone_ext>
      <email>christoph.spinner@mri.tum.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Spinner, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis - Infectomed</name>
      <address>
        <city>Stuttgart</city>
        <zip>70197</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Egetemeyr, Dr.</last_name>
      <phone>0049 711 6155</phone>
      <phone_ext>320</phone_ext>
      <email>praxis@schwabstrasse59.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Egetemeyr, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg, Medizinische Klinik II, Schwerpunkt Infektiologie</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hartwig Klinker, Prof. Dr.</last_name>
      <phone>0049 931 2014</phone>
      <phone_ext>0043</phone_ext>
      <email>klinker_h@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Hartwig Klinker, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 24, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute hepatitis C virus (HCV) infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

